Organon & Co. (NYSE:OGN) Stock Rating Lowered by Wall Street Zen

Organon & Co. (NYSE:OGN) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other brokerages have also issued reports on OGN. Morgan Stanley dropped their target price on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 11th. Barclays initiated coverage on shares of Organon & Co. in a report on Tuesday, December 9th. They issued an “underweight” rating and a $7.50 price objective on the stock. Piper Sandler lowered shares of Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price objective on the stock. in a research report on Monday, October 27th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Organon & Co. in a research report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Organon & Co. from $14.00 to $12.00 and set an “underweight” rating on the stock in a research note on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat, Organon & Co. currently has a consensus rating of “Reduce” and a consensus target price of $8.38.

Organon & Co. Trading Down 1.0%

Shares of NYSE:OGN opened at $8.51 on Friday. Organon & Co. has a 12 month low of $6.18 and a 12 month high of $17.23. The company has a quick ratio of 1.20, a current ratio of 1.75 and a debt-to-equity ratio of 9.69. The company’s fifty day simple moving average is $7.80 and its 200 day simple moving average is $8.72. The firm has a market cap of $2.21 billion, a price-to-earnings ratio of 4.43, a PEG ratio of 1.82 and a beta of 0.58.

Organon & Co. (NYSE:OGN) last announced its earnings results on Monday, November 10th. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.93 by $0.08. Organon & Co. had a net margin of 7.95% and a return on equity of 143.47%. The firm had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period in the prior year, the business earned $1.38 EPS. As a group, research analysts forecast that Organon & Co. will post 3.68 EPS for the current fiscal year.

Institutional Investors Weigh In On Organon & Co.

Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its position in Organon & Co. by 11.3% during the third quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock worth $383,715,000 after buying an additional 3,650,860 shares during the last quarter. Norges Bank bought a new position in shares of Organon & Co. during the 2nd quarter worth approximately $19,778,000. AQR Capital Management LLC increased its holdings in shares of Organon & Co. by 136.1% during the 2nd quarter. AQR Capital Management LLC now owns 3,254,884 shares of the company’s stock worth $31,507,000 after acquiring an additional 1,876,264 shares during the last quarter. UBS Group AG raised its stake in Organon & Co. by 55.2% in the 4th quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock valued at $30,795,000 after acquiring an additional 1,527,492 shares during the period. Finally, Balyasny Asset Management L.P. lifted its holdings in Organon & Co. by 102.1% during the 3rd quarter. Balyasny Asset Management L.P. now owns 2,240,149 shares of the company’s stock valued at $23,925,000 after purchasing an additional 1,131,941 shares during the last quarter. 77.43% of the stock is owned by institutional investors.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.